The efficacy of the interleukin 17 inhibitor ixekizumab in psoriatic arthritis: data from real clinical practice
https://doi.org/10.14412/1996-7012-2021-3-86-90
Abstract
The article describes the peculiarities of drug provision for patients with psoriatic arthritis (PsA) in the Republic of Karelia. We present a clinical case of effective treatment with interleukin 17 inhibitor ixekizumab (IXE) in a randomized clinical trial and real clinical practice in a patient with PsA. The distinctive feature of this case is the severity of PsA course that was not controlled by standard methods of therapy. IXE treatment was characterized by a rapid clinical improvement of both articular and skin symptoms and subsequent achievement of remission, which lasted for 3 years (on the therapy). The forced interruption of the treatment led to the relapse of the disease in a short amount of time. In 2 years IXE therapy was resumed; after 6 months of continuing treatment a stable remission of PsA was achieved. The patient is still in clinical remission (on therapy).
About the Authors
I. M. Marusenko
Petrozavodsk State University, medical institute, department of hospital therapy
Russian Federation
Russian Federation
Irina Mikhailovna Marusenko
33, Prospekt Lenina, Petrozavodsk 185910, Russia
O. N. Sakovich
V.A. Baranov republican hospital
Russian Federation
Russian Federation
3, Pirogova St., Petrozavodsk 185910, Russia
References
1. Korotaeva TV, Korsakova YuL, Loginova EYu, et al. Psoriatic arthritis. Clinical guidelines for diagnosis and treatment. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2018;12(2):22-35. (In Russ.). doi: 10.14412/1996-7012-2018-2-22-35
2. O’Rielly DD. A review of ixekizumab in the treatment of psoriatic arthritis. Expert Rev Clin Immunol. 2018 Dec;14(12):993-1002. doi: 10.1080/1744666X.2018.1540931. Epub 2018 Nov 5.
3. Gladman DD. Clinical features and diagnostic considerations in psoriatic arthritis. Rheum Dis Clin North Am. 2015 Nov;41(4): 569-79. doi: 10.1016/j.rdc.2015.07.003. Epub 2015 Sep 5.
4. Korotaeva TV, Korsakova YuL. Psoriatic arthritis: classification, clinical picture, diagnosis, treatment. Nauchno-prakticheskaya revmatologiya. 2018;56(1):60-9. (In Russ.).
5. Gladman DD, Stafford-Brady F, Chang CH, et al. Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol. 1990 Jun;17(6):809-12.
6. McHugh NJ, Balachrishnan C, Jones SM. Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology (Oxford). 2003 Jun;42(6): 778-83. doi: 10.1093/rheumatology/keg217. Epub 2003 Mar 14.
7. Raychaudhuri SP, Wilken R, Sukhov AC, et al. Management of psoriatic arthritis: Early diagnosis, monitoring of disease severity and cutting edge therapies. J Autoimmun. 2017 Jan;76:21-37. doi: 10.1016/j.jaut.2016.10.009. Epub 2016 Nov 9.
8. Smolen J, Schols M, Braun J, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis. 2018 Jan;77(1):3-17. doi: 10.1136/annrheumdis-2017-211734. Epub 2017 Jul 6.
9. Korotaeva TV, Nasonov EL. Standards for the treatment of psoriatic arthritis. Nauchnoprakticheskaya revmatologiya. 2009;47(3): 29-37. (In Russ.).
10. Korsakova YuL, Korotaeva TV. Modern pharmacotherapy of psoriatic arthritis. Nauchno-prakticheskaya revmatologiya. 2019; 57(1):75-82. (In Russ.).
11. Korotaeva TV. Progress in the treatment of psoriatic arthritis. Farmateka. 2015;(7):21-7. (In Russ.).
12. Lila AM, Nasonov EL, Korotaeva TV. Psoriatic arthritis: pathogenetic features and innovative methods of therapy. Nauchnoprakticheskaya revmatologiya. 2018;56(6): 685-91. (In Russ.).
13. Gossec L, Baraliakos Х, Kerschbaumer А, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020 Jun;79(6):700-12. doi: 10.1136/annrheumdis-2020-217159.
14. Russian Society of Dermatovenerologists and Cosmetologists. All-Russian Public Organization «Association of Rheumatologists of Russia». Federal'nye klinicheskie rekomendatsii po vedeniyu bol'nykh psoriaticheskim artritom [Federal clinical guidelines for the management of patients with psoriatic arthritis]. Moscow; 2015. 41 p.
15. Bakulev AL, Fitileva TV, Novoderezhkina EA, et al. Psoriasis: clinical and epidemiological features and issues of therapy. Vestnik dermatologii i venerologii. 2018;(3):67–76. (In Russ.).
16. Boehncke WH, Schon MP. Psoriasis. Lancet. 2015 Sep 5;386(9997):983-94. doi: 10.1016/S0140-6736(14)61909-7. Epub 2015 May 27.
17. Liu L, Lu J, Allan BW, et al. Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A. J Inflamm Res. 2016 Apr 19; 9:39-50. doi: 10.2147/JIR.S100940. eCollection 2016.
18. Dadalova AM, Vasilenko EA, Samigullina RR, Mazurov VI. Successful use of the interleukin-17A inhibitor (ixekizumab) in the treatment of psoriatic arthritis. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2020;14(4):165–70. (In Russ.). doi: 10.14412/1996-7012-2020-4-165-170
19. Mease PJ, van der Heijde D, Ritchlin CT, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017 Jan;76(1):79-87. doi: 10.1136/annrheumdis-2016-209709. Epub 2016 Aug 23.
20. Van der Heijde D, Gladman DD, Kishimoto M, et al. Efficacy and safety of Ixekizumab in patients with active psoriatic arthritis: 52- week results from a phase III study (SPIRIT-P1). J Rheumatol. 2018 Mar; 45(3):367-77. doi: 10.3899/jrheum.170429. Epub 2017 Dec 15.
Review
For citations:
Marusenko IM, Sakovich ON. The efficacy of the interleukin 17 inhibitor ixekizumab in psoriatic arthritis: data from real clinical practice. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2021;15(3):86-90. (In Russ.) https://doi.org/10.14412/1996-7012-2021-3-86-90
Views:
607
Email this article 